In Case You Missed It
Before the Bell
Jim Cramer's Daily Booyah
Winners & Losers
SOURCE Regulus Therapeutics Inc.
Here's how to rake in the gains.
Adam Feuerstein compiles a list of questions, thoughts, declarations, catalysts and observations about biotech stocks to help investors prepare for the year ahead.
A look back at the year's worth of Adam Feuerstein's biotech tweets.
Alnylam Pharmaceuticals' (ALNY) phase III trial for its patisiran drug was recommended to continue by the trial's data monitoring committee.
©1996-2017 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.